Cargando…
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital betw...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565543/ https://www.ncbi.nlm.nih.gov/pubmed/32937800 http://dx.doi.org/10.3390/jcm9092961 |
_version_ | 1783595956915142656 |
---|---|
author | Brunetti, Luigi Diawara, Oumou Tsai, Andrew Firestein, Bonnie L. Nahass, Ronald G. Poiani, George Schlesinger, Naomi |
author_facet | Brunetti, Luigi Diawara, Oumou Tsai, Andrew Firestein, Bonnie L. Nahass, Ronald G. Poiani, George Schlesinger, Naomi |
author_sort | Brunetti, Luigi |
collection | PubMed |
description | The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials. |
format | Online Article Text |
id | pubmed-7565543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75655432020-10-26 Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 Brunetti, Luigi Diawara, Oumou Tsai, Andrew Firestein, Bonnie L. Nahass, Ronald G. Poiani, George Schlesinger, Naomi J Clin Med Article The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials. MDPI 2020-09-14 /pmc/articles/PMC7565543/ /pubmed/32937800 http://dx.doi.org/10.3390/jcm9092961 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Brunetti, Luigi Diawara, Oumou Tsai, Andrew Firestein, Bonnie L. Nahass, Ronald G. Poiani, George Schlesinger, Naomi Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title | Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title_full | Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title_fullStr | Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title_full_unstemmed | Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title_short | Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 |
title_sort | colchicine to weather the cytokine storm in hospitalized patients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565543/ https://www.ncbi.nlm.nih.gov/pubmed/32937800 http://dx.doi.org/10.3390/jcm9092961 |
work_keys_str_mv | AT brunettiluigi colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT diawaraoumou colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT tsaiandrew colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT firesteinbonniel colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT nahassronaldg colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT poianigeorge colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 AT schlesingernaomi colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19 |